ASCO 2018 | PEMBROSARC: pembrolizumab combinations for advanced sarcoma

Maud Toulmonde

Checkpoint inhibitors are an exciting therapy across a range of cancer types. Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Maud Toulmonde, MD, of the Institut BergoniƩ, Bordeaux, France, discusses the PEMBROSARC trial (NCT02406781), which investigated the use of pembrolizumab plus metronomic cyclophosphamide in advanced sarcoma.

Share this video